Drug Profile

Research programme: T cell therapies - A2 Biotherapeutics/Merck & Co

Alternative Names: CAR T module (Tmod) T-cell system; Tmod CAR T cells

Latest Information Update: 28 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator A2 Biotherapeutics
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Solid tumours
No development reported Lymphoma

Most Recent Events

28 Feb 2025 No recent reports of development identified for preclinical development in Lymphoma in USA (Parenteral)
12 Nov 2021 Pharmacodynamics data from a preclinical study in Solid tumours released by A2 Biotherapeutics
23 Dec 2020 A2 Biotherapeutics and Merck agree to co-develop an allogeneic T-cell therapy for Solid tumours

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com